Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Poole, Ashley
NCT06419582: BHV-7000 Acute Treatment of Bipolar Mania	Active, not recruiting	2/3	256	US	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Bipolar Disorder	03/25	04/25
NCT06419608: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression	Recruiting	2	300	US	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Major Depressive Disorder	05/25	07/25
Karnes, Tyler
RISE 2, NCT06132893: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy	Recruiting	2/3	390	Europe, US, RoW	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Focal Epilepsy	08/25	09/25
SHINE, NCT06425159: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures	Recruiting	2/3	242	Europe, US, RoW	BHV-7000, Placebo	Biohaven Therapeutics Ltd.	Generalized Epilepsy	07/26	07/27
NCT06737042: Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants	Not yet recruiting	2	285	US	GZR18, Tirzepatide	Gan and Lee Pharmaceuticals, USA	Obesity and Overweight	02/26	06/26